Citations

Clear

942 citation(s) found for "Shi, M".

Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)
Song, Mingyang , Hull, Mark A. , Shi, Qian , Giovannucci, Edward L. , Blarigan, Erin L. Van , Meyerhardt, Jeffrey A. , Zemla, Tyler J, Limburg, Paul J. , Meyerhardt, Jeffrey A , Shi, Qian , Song, Mingyang , Ou, Fang‐Shu , Zemla, Tyler , Alberts, Steven R. , Sinicrope, Frank A. , Chan, Andrew T.

Mayo Clinic

International Journal of Cancer | January 9, 2019 | Volume: 145 | Issue: 2 | Pages: 380-389

10.1002/ijc.32113 | PMID 30623420 Get It

Marine omega‐3 polyunsaturated fatty acids (MO3PUFAs) have anticancer properties and may improve colon cancer survival. However, it remains unknown whether the benefit differs by tumor molecular subtype. We examined data from a phase III randomized trial of FOLFOX or FOLFOX + cetuximab among 1,735 stage III colon cancer patients who completed a dietary questionnaire at enrollment. Multivariable hazard ratios and 95% confidence intervals (CIs) were calculated for the association between MO3PUFA and disease‐free survival (DFS) and overall survival according toKRASandBRAFV600Emutations and DNA mismatch repair (MMR) status. Higher MO3PUFA intake was associated with improved 3‐year DFS forKRASwild‐type tumors (77%vs. 73%; HR: 0.84; 95% CI: 0.67–1.05) but notKRAS‐mutant tumors (64%vs. 70%; HR: 1.30; 95% CI: 0.97–1.73;Pinteraction= 0.02). Similar heterogeneity was found by MMR (Pinteraction= 0.14): higher MO3PUFA was associated with better 3‐year DFS for tumors with deficient MMR (72%vs. 67%) but not proficient MMR (72%vs. 72%). No heterogeneity was found byBRAFV600Emutation. Similar findings were obtained for overall survival. In conclusion, we found a suggestive beneficial association between higher MO3PUFA intake and improved survival among stage III colon cancer patients with wild‐typeKRASand deficient MMR. Given the relatively small number of cases with tumor molecular assessments, further studies, preferably through pooled analyses of multiples cohorts, are needed to validate our findings.
The impact of stress on epidermal barrier function: an evidence‐based review
Maarouf, Melody , Maarouf, C.L., Yosipovitch, Gil , Shi, Vivian Y. , Maarouf, M , Yosipovitch, G , Shi, Vivian Y

Mayo Clinic

British Journal of Dermatology | January 8, 2019 | Volume: 181 | Issue: 6 | Pages: 1129-1137

10.1111/bjd.17605 | PMID 30614527 Get It

Ikaros expression levels to predict response and survival following pomalidomide and dexamethasone in multiple myeloma (MM).
Zhu, Yuan Xiao , Shi, Chang‐Xin, Bruins, Laura A., Schmidt, Jessica, Chang, Xiu-Bao, Moulun, Luo, Jedlowski, Patrick , LaPlant, Betsy, Laumann, Kristina, Lacy, Martha Q. , Champion, Mia D., Stewart, A. Keith, Braggio, Esteban , Kortüm, K. Martin , Chang, Xiu-Bao, Langlais, Paul R. , Moulun, Luo, Fonseca, Rafaël , Bergsagel, P. Leif , Mıkhael, Joseph , Stewart, A. Keith

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8540-8540

10.1200/jco.2014.32.15_suppl.8540 Get It

Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.
Saad, Everardo D. , Coart, Elisabeth , Sommeijer, Dirkje W. , Meyers, Jeffrey P., Hecht, J. Randolph , Hurwitz, Herbert I. , Tol, Jolien , Fuchs, Charles S. , Souglakos, John , Kabbinavar, Fairooz F. , Gramont, Aimery de , Group, for the ARCAD, Shi, Qian , Zalcberg, John , Burzykowski, Tomasz , Hoff, Paulo M. , Tebbutt, Niall C. , Díaz‐Rubio, Eduardo , Falcone, Alfredo , Sargent, Daniel J. , Buyse, Marc , Group, for the ARCAD

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3578-3578

10.1200/jco.2014.32.15_suppl.3578 Get It

Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.
Sommeijer, Dirkje W. , Saad, Everardo D. , Coart, Elisabeth , Meyers, Jeffrey P., Seymour, Michel , Goldberg, Richard M. , Douillard, Jean‐Yves , Punt, Cornelis J. A. , Tournigand, Christophe , Chibaudel, Benoist , Gramont, Aimery de , group, for the ARCAD, Seymour, Matthew T , Shi, Qian , Buyse, Marc , Burzykowski, Tomasz , Maughan, Tim , Adams, Richard , Saltz, Leonard B. , Schmoll, Hans‐Joachim , Sargent, Daniel J. , Zalcberg, John , group, for the ARCAD, Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3538-3538

10.1200/jco.2014.32.15_suppl.3538 Get It

Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]).
Yoon, Harry H. , Goldberg, Richard M. , Thibodeau, Stephen N. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3536-3536

10.1200/jco.2014.32.15_suppl.3536 Get It

Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].
Thibodeau, Stephen N. , Goldberg, Richard M. , Sinicrope, Frank A. , Shi, Qian , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3512-3512

10.1200/jco.2014.32.15_suppl.3512 Get It

Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.
Thibodeau, Stephen N. , Gallinger, Steven , Monges, Geneviève, Pogue–Geile, Katherine L. , Roth, Arnaud, Pavey, Emily S., Kim, George P., Group, ACCENT Collaborative, Sargent, Daniel J. , Shi, Qian , Yothers, Greg , Tejpar, Sabine , Bertagnolli, Monica M. , André, Thierry , Labianca, Roberto , Hamilton, Stanley R. , Paik, Soonmyung , Klingbiel, Dirk , Sinicrope, Frank A. , Group, ACCENT Collaborative

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3507-3507

10.1200/jco.2014.32.15_suppl.3507 Get It

Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database.
Salem, Mohamed E. , Yin, Jun , Goldberg, Richard M. , Pederson, Levi , Grothey, Axel, Gramont, Aimery de , Wolmark, Norman , Alberts, Steven R. , Taı̈eb, Julien , Marshall, John L , Lonardi, Sara , Yoshino, Takayuki , Kerr, Rachel , Yothers, Greg , André, Thierry , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 728-728

10.1200/jco.2018.36.4_suppl.728 Get It

728 Background: Adjuvant FOLFOX therapy for stage II patients remains controversial, and selection criteria are imprecise. We examined the trend of disease-free survival (DFS: time to recurrence or death, whichever occurs first); time to recurrence (TTR: time to recurrence, censored at death without recurrence); survival after recurrence (SAR); and overall survival (OS) of pts treated with FOLFOX over a ten-year period. Methods: Outcomes of pts with stage II colon cancer enrolled in 6 adjuvant trials receiving FOLFOX alone were analyzed. Pt enrollment period was dichotomized as old (1998 – 2003) vs. new era (2004 – 2009) based on the FDA approval date of bevacizumab. 3/5yr event-free rates were estimated using adjusted Kaplan-Meier methods. Outcomes were compared between the two eras by multivariate Cox model. To control for potential confounding effects, all analyses were adjusted for age, gender, performance score, T stage, number of lymph nodes (LNs) examined, tumor side, and histologic grade. Results: In total, 1,122 pts with stage II were identified; 71% and 29% were treated in the old and new era, respectively. Pts enrolled in the new era were significantly younger and more likely to have higher tumor-grade and right-sided tumors compared to old era. More pts in the new era (71%) had ≥12 LNs examined compared to the old era (53%). After adjusting for potential confounding effects, no difference in DFS, TTR, SAR or OS between old and new eras was found (Table). Although median SAR increased from 13.6 to 26 months over time, this was not statistically significant, likely due to lack of power. An increased TTR over time (HRadj. 0.41, padj.= 0.002) was observed in pts with ≥12 LNs examined (3-yr TTR: 92% in old era vs. 96% in new era), but not pts with <12 LNs examined (pinteraction = 0.04). Conclusions: In stage II colon cancer pts who received adjuvant FOLFOX, no significant increase of DFS or OS was observed over time. However TTR was longer only in pts with ≥12 LNs examined. [Table: see text]
Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.
Salem, Mohamed E. , Yin, Jun , Goldberg, Richard M. , Pederson, Levi , Grothey, Axel, Gramont, Aimery de , Wolmark, Norman , Alberts, Steven R. , Taı̈eb, Julien , Marshall, John L , Lonardi, Sara , Yoshino, Takayuki , Kerr, Rachel , Yothers, Greg , André, Thierry , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 724-724

10.1200/jco.2018.36.4_suppl.724 Get It

724 Background: Adjuvant FOLFOX is the standard of care for pts with stage III colon cancer and a platform to test new agents. Improvements in supportive care and development of newer treatments for metastatic disease impact the overall outcome of pts treated with adjuvant therapy. We examined the trend of disease-free survival (DFS), survival after recurrence (SAR), and overall survival (OS) of pts treated with FOLFOX over a ten-year period. Methods: Outcomes of colon cancer pts enrolled in 6 adjuvant trials receiving FOLFOX alone were analyzed. Pt enrollment period was dichotomized as old (1998 – 2003) vs. new era (2004 – 2009) based on the FDA approval date of bevacizumab. 3/5yr event-free rates were estimated by adjusted Kaplan-Meier methods. Outcomes were compared between the two eras by Cox model. To control for potential confounding effects, all analyses were adjusted for age, gender, performance score, T/N stage, tumor sidedness and histologic grade. Results: In total, 7,230 pts (stage II [n = 1122]; stage III [n = 6,108]) were identified; 32% and 68% were treated in the old and new era, respectively. Stage III pts enrolled in the new era were significantly younger, more likely to have T4/N2 disease, higher tumor grade, and left-sided tumors. After adjusting for pt characteristics, no difference in DFS was seen over time. However prolonged SAR and OS were observed in pts treated in the new era (Table). 5yr OS increased from 76% to 80% over time. Median SAR improved from 14.8 to 26.4 months. Conclusions: Stage III colon cancer pts who received adjuvant FOLFOX experienced significant improvements in SAR and OS—but not DFS—over time. In view of the improvements in OS and nearly doubled SAR, the optimal duration of OS follow-up to evaluate the benefits of adjuvant therapy (currently 5 years) should be reassessed, and ACCENT investigators are planning to conduct these additional analyses using their large pooled-trial database. [Table: see text]